A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results

Annals of Occupational Hygiene

Volumn 55, Issue 8, 2011, Pages 841-864

  Jongeneelen, Frans J ^a   Berge, Wil F Ten ^b  

^a IndusTox Consult   (Netherlands)

^b Santoxar ^*  (Netherlands)

Author keywords

biomarker of exposure; blood; body burden; internal exposure; PBTK model; prediction, urine

Indexed keywords

BIOMONITORING; BODY BURDEN; COMPUTATIONAL TOOLS; DERMAL EXPOSURE; DERMAL UPTAKE; ENVIRONMENTAL CHEMICALS; EXPERIMENTAL OBSERVATION; GENERIC MODELS; HUMAN BODIES; INDEPENDENT PARAMETERS; INTERNAL EXPOSURE; METHYL TERT BUTYL ETHER; MICHAELIS-MENTEN KINETIC; MODEL PREDICTION; MODEL-PREDICTED CONCENTRATIONS; MS EXCEL; OBSERVED DATA; OCCUPATIONAL EXPOSURE; PARENT COMPOUNDS; PARTITION COEFFICIENT; PBTK-MODEL; PHYSICOCHEMICAL PROPERTY; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS; QUANTITATIVE STRUCTURE PROPERTY RELATIONSHIPS; SKIN CONTACT; SPREADSHEET APPLICATIONS; TOXICOKINETICS; TRANSDERMAL; VISUAL BASIC;

BIOMOLECULES; BLOOD; CHEMICAL PROPERTIES; COMPUTER SIMULATION; DIFFERENTIAL EQUATIONS; ETHANOL; FORECASTING; INDICATORS (CHEMICAL); METABOLISM; METABOLITES; PHYSIOLOGY; TISSUE;

PHYSIOLOGICAL MODELS;

ORGANIC COMPOUND;

ARTICLE; BIOLOGICAL MODEL; CHEMICAL MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; EXPOSURE; HUMAN; MASS SCREENING; METHODOLOGY; OCCUPATIONAL EXPOSURE; PHYSIOLOGY; SKIN ABSORPTION; TISSUE DISTRIBUTION;

COMPUTER SIMULATION; HUMANS; INHALATION EXPOSURE; MASS SCREENING; MODELS, BIOLOGICAL; MODELS, CHEMICAL; OCCUPATIONAL EXPOSURE; ORGANIC CHEMICALS; SKIN ABSORPTION; SOFTWARE; TISSUE DISTRIBUTION;

EID: 80054769484     PISSN: 00034878     EISSN: 14753162     Source Type: Journal    
DOI: 10.1093/annhyg/mer075     Document Type: Article

References (76)

1. AIHA. (2010) Exposure Assessment Strategies Committee. IHMOD spreadsheet, January 2010. Available at http://www.aiha.org/insideaiha/volunteergroups/ Documents/EASIHMOD%20HELP.pdf. Accessed 6 September 2011.
2. Amberg A, Rosner E, Dekant W. (1999) Biotransformation and kinetics of excretion of methyl-tert-butyl ether in rats and humans. Toxicol Sci; 51: 1-8. (Pubitemid 29439225)
3. Amberg A, Rosner E, Dekant W. (2001) Toxicokinetics of methyl tert-butyl ether and its metabolites in humans after oral exposure. Toxicol Sci; 61: 62-7. (Pubitemid 32409688)
4. Bader M, Wrbitzky R, Blaszkewicz M et al. (2008) Human volunteer study on the inhalational and dermal absorption of N-methyl-2-pyrrolidone (NMP) from the vapour phase. Arch Toxicol; 82: 13-20.
5. Bader M, Wrbitzky R, BlaszkewiczMet al. (2007) Human experimental exposure study on the uptake and urinary elimination of N-methyl-2-pyrrolidone (NMP)during simulated workplace conditions. Arch Toxicol; 81: 335-46. (Pubitemid 46701592)
6. Bahima J, Cert A, Menéndez-Gallego M. (1984) Identification of volatile metabolites of inhaled n-heptane in rat urine. Toxicol Appl Pharmacol; 76: 473-82. (Pubitemid 15189461)
7. Beliveau M, Krishnan K. (2005) A spreadsheet program for modeling quantitative structure-pharmacokinetic relationships for inhaled volatile organics in humans. SAR QSAR Environ Res; 16: 63-77. (Pubitemid 40623243)
8. Beliveau M, Lipscomb J, Tardif R, Krishnan K. (2005) Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. Chem Res Toxicol; 18: 475-85. (Pubitemid 40393169)
9. Blaauboer BJ, Bayliss MK, Castell JV et al. (1996) The use of biokinetics and in vitro methods in toxicological risk evaluation. ALTA; 24: 473-97.
10. Borak J, Sirianni G, Cohen H et al. (2002) Biological versus ambient exposure monitoring of creosote facility workers. Occup Environ Med; 44: 310-19. (Pubitemid 34412019)
11. Brightman FA, Leahy DE, Searle GE, Thomas S. (2006) Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos; 34: 94-101. (Pubitemid 43042650)
12. Cahill TM, Cousins I, Mackay D. (2003) Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants. Environ Toxicol Chem; 22: 26-34. (Pubitemid 35471317)
13. Clewell HJ, III, Gentry PR, Covington TR, Gearhart JM. (2000) Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect; 108 (Suppl. 2): 283-305. (Pubitemid 30420987)
14. Clewell HJ et al. (2001) Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci Total Environ; 274: 37-66. (Pubitemid 32591381)
15. Collins AS, Sumner SC, Borghoff SJ, Medinsky MA. (1999) A physiological model for tert-amyl methyl ether and tertamyl alcohol: Hypothesis testing of model structures. Toxicol Sci; 49: 15-28. (Pubitemid 29266421)
16. Corley RA, Bormett GA, Ghanayem BI. (1994) Physiologically- based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol Appl Pharmacol; 129: 61-79. (Pubitemid 24352623)
17. Corley RA, Gordon SM, Wallace LA. (2000) Physiologically based pharmacokinetic modeling of the temperaturedependent dermal absorption of chloroform by humans following bath water exposures. Toxicol Sci; 53: 13-23. (Pubitemid 30043598)
18. Corley RA, Markham DA, Banks C et al. (1997) Physiologically- based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapour by humans. Fundam Appl Toxicol; 39: 120-30.
19. DeJongh J, Verhaar HJ, Hermens JL. (1997) A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol; 72: 17-25. (Pubitemid 28062388)
20. DeWoskin RS, Thompson CM. (2008) Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol; 51: 66-86.
21. ECHA. (2008a) Guidance on information requirements and chemical safety assessment Chapter R.7c-endpoint specific guidance. Appendix R.7.12-1 Toxicokinetics-Physiological Factors. Available at http://guidance.echa.europa. eu. Accessed 7 September 2011.
22. ECHA. (2008b) Guidance on information requirements and chemical safety assessment Chapter R8. Characterisation of dose [concentration]-response for human health. Appendix 8-4. Available at http://guidance.echa.europa.eu.
23. Elovaara E, Heikkilä P, Pyy L et al. (1995) Significance of dermal and respiratory uptake in creosote workers: Exposure to polycyclic aromatic hydrocarbons and urinary excretion of 1-hydroxypyrene. Occup Environ Med; 52: 196-203.
24. Franks SJ, Spendiff MK, Cocker J et al. (2006) Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol. Toxicol Lett; 162: 164-73. (Pubitemid 43243137)
25. Gale GE, Torre-Bueno JR, Moon RE et al. (1985) Ventilation- perfusion inequality in normal humans during exercise at sea level and simulated altitude. J Appl Physiol; 58: 978-88.
26. Griffiths M. (1974) Introduction to human physiology In Chapter 27: The function of the kidney. New York: MacMillan Publishing Co. ISBN 0-02-347220-0.
27. Haddad S, Pelekis M, Krishnan K. (1996) A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol Lett; 85: 113-26. (Pubitemid 26128762)
28. Haddad S et al. (1999) Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. Toxicol Appl Pharmacol; 161: 249-57. (Pubitemid 30041797)
29. Haddad S, Charest-Tardif G, Tardif R, Krishnan K. (2000) Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol Appl Pharmacol; 167: 199-209.
30. Hamelin G, Charest-Tardif G, Truchon G et al. (2005) Physiologically based modeling of n-hexane kinetics in humans following inhalation exposure at rest and under physical exertion: Impact on free 2,5-hexanedione in urine and on n-hexane in alveolar air. J Occup Environ Hyg; 2: 86-97.
31. Johanson G. (1986) Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. Toxicol Lett; 34: 23-31. (Pubitemid 17201269)
32. Johanson G, Boman A. (1991) Percutaneous absorption of 2- butoxyethanol vapour in human subjects. Br J Ind Med; 48: 788-92.
33. Jones K, Cocker J. (2003) A human exposure study to investigate biological monitoring methods for 2-butoxyethanol. Biomarkers; 8: 360-70. (Pubitemid 37509170)
34. Jongeneelen FJ, Anzion RBM, Henderson PT. (1987a) Determination of hydroxylated metabolites of polycyclic aromatic hydrocarbons in urine. J Chromatogr; 413: 227-32. (Pubitemid 17005010)
35. Jongeneelen FJ, Anzion RB, Scheepers PT et al. (1988) 1-Hydroxypyrene in urine as a biological indicator of exposure to polycyclic aromatic hydrocarbons in several work environments. Ann Occup Hyg; 32: 35-43. (Pubitemid 18097211)
36. Jongeneelen FJ, Hermans F, Anzion RBM et al. (1987b) Interindividual differences in hydroxylation of benzo(a)pyrene and pyrene in human liver preparations. Chapter 2 of PhD Thesis. University of Nijmegen-NL Nijmegen: Scientific Publishers. ISBN 90-9001458-6.
37. Kim D, Andersen ME, Pleil JD et al. (2007) Refined PBPK model of aggregate exposure to methyl tertiary-butyl ether. Toxicol Lett; 169: 222-35. (Pubitemid 46437429)
38. Kramer A, Below H, Bieber N et al. (2007) Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans. BMC Infect Dis; 11: 117.
39. Krewski D,Withey JR, Ku LF, Andersen ME. (1994) Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment. Environ Health Perspect; 102 (Suppl. 11): 37-50.
40. Leavens TL, Borghoff SJ. (2009) Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to alpha2u- globulin. Toxicol Sci; 109: 321-35.
41. Levitt DG. (2002) PKQuest: A general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol; 2: 5.
42. Licata AC, Dekant W, Smith CE et al. (2001) A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: Implementing sensitivity and variability analyses. Toxicol Sci; 62: 191-204. (Pubitemid 32707733)
43. Ligocka D, Lison D, Haufroid V. (2003) Contribution of CYP2E1 to N-methylpyrrolidone metabolism. Arch Toxicol; 77: 261-6.
44. Luecke RH, Pearce BA, Wosilait WD et al. (2008) Windows based general PBPK/PD modeling software. Comput Biol Med; 38: 962-78.
45. Luukkanen L, Mikkola J, Forsman T et al. (2001) Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: Development of a high-sensitivity glucuronidation assay for human tissue. Drug Metab Dispos; 29: 1096-101. (Pubitemid 32660527)
46. McCarley KD, Bunge AL. (1998) Physiologically relevant one-compartment pharmacokinetic models for skin. 1. Development Of models. J Pharm Sci; 87: 1264.
47. McCarley KD, Bunge AL. (2000) Physiologically relevant twocompartment pharmacokinetic models for skin. J Pharm Sci; 89: 1212-35.
48. Medinsky MA, Singh G, Bechtold WE et al. (1990) Disposition of three glycol ethers administered in drinking water to male F344/N rats. Toxicol Applied Pharmacol; 102: 443-55. (Pubitemid 20096678)
49. Meulenberg CJW, Vijverberg HPM. (2000) Emperical relations predicting human and rat tissue:air partition coefficients of volatile organic compounds. Toxicol Appl Pharmacol; 165: 206-21.
50. Perbellini L, Brugnone F, Caretta D et al. (1985) Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. Br J Ind Med; 42: 162-7. (Pubitemid 15076873)
51. Perbellini L, Brugnone F, Cocheo Vet al. (1986) Identification of the n-heptane metabolites in rat and human urine. Arch Toxicol; 58: 229-34. (Pubitemid 16023437)
52. Peyret T, Poulin P, Krishnan KA. (2010) Unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol; 249: 197-207.
53. Poet TS, Kirman CR, Bader M et al. (2010) Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling. Toxicol Sci; 113: 468-82.
54. Poulin P, Theil FP. (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci; 91: 1358-70. (Pubitemid 34651198)
55. Ramsey JC, Andersen ME. (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol; 73: 159-75. (Pubitemid 14131618)
56. Reddy MB, McCarley KD, Bunge AL. (1998) Physiologically relevant one-compartment pharmacokinetic models for skin. 2. Comparison of models when combined with a systemic pharmacokinetic model. J Pharm Sci; 87: 482-90. (Pubitemid 28175810)
57. Reddy MB, Looney RJ, Utell MJ et al. (2007) Modeling of human dermal absorption of octamethylcyclotetrasiloxane (D(4)) and decamethylcyclopentasiloxane (D(5)). Toxicol Sci; 99: 422-31. (Pubitemid 351753060)
58. Rossbach B, Kegel P, Letzel S. (2010) Effects of an experimental exposure to 500 PPM nheptane on levels of n-haptene and its metabolites in blood. Poster Int Symposium BioMonitoring, 6/8 sept 2010. Helsinki, Finland: FIOH.
59. RSC. (2010) OpenEye, ChemSpider Database. Building community for chemists. Available at http://www.chemspider.com/.
60. Spaan S, FransmanW,Warren N et al. (2010) Variability of biomarkers in volunteer studies: The biological component. Toxicol Lett; 198: 144-51.
61. Strickland P, Kang D, Sithisarankul P. (1996) Polycyclic aromatic hydrocarbon metabolites in urine as biomarkers of exposure and effect. Environ Health Perspect; 104 (Suppl. 5): 927-32. Review. (Pubitemid 26402332)
62. Szutowski MM, Rakoto JS. (2009) Multiplicity of n-heptane oxidation pathways catalyzed by cytochrome P450. J Biochem Mol Toxicol; 23: 287-94.
63. Tardif R, Droz PO, Charest-Tardif G et al. (2002) Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. Toxicol Lett; 134: 155-63. (Pubitemid 35007299)
64. Teeguarden JG, Waechter JM Jr, Clewell HJ 3rd et al. (2005) Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Toxicol Sci; 85: 823-38. (Pubitemid 40851976)
65. ten Berge W. (2009) A simple dermal absorption model: Derivation and application. Chemosphere; 75: 1440-5.
66. Umulis DM, Gürmen NM, Singh P et al. (2005) A physiologically based model for ethanol and acetaldehyde metabolism in human beings. Alcohol; 35: 3-12. Review. (Pubitemid 40726306)
67. US-EPA. (2006) Exposure Related Dose Estimating Model (ERDEM). Available at http://www.epa.gov. Accessed 7 September 2011.
68. US-EPA. (2009) Episuite 4.0. Estimation Program Interface (EPI) Suite. USEPA. Available at http://www.epa.gov/opptintr/exposure/pubs/episuitedl.htm. Accessed 7 September 2011.
69. van der Merwe D, Brooks JD, Gehring R et al. (2006) A physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicol Sci; 89: 188-204. (Pubitemid 43013767)
70. van de Waterbeemd H, Gifford E. (2003) ADMET in silico modelling: Towards prediction paradise? Nat Rev Drug Discov; 2: 192-204. (Pubitemid 37361664)
71. Van Rooij JG, Van Lieshout EM, Bodelier-Bade MM et al. (1993) Effect of the reduction of skin contamination on the internal dose of creosote workers exposed to polycyclic aromatic hydrocarbons. Scand J Work Environ Health; 19: 200-7. (Pubitemid 23207334)
72. Willmann S, Lippert J, SchmittW. (2005) From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol; 1: 159-68.
73. Wilschut A, ten Berge WF, Robinson PJ et al. (1995) Estimating skin permeation. The validation of five mathematical skin permeation models. Chemosphere; 30: 1275-96.
74. Woodard HQ, White DR. (1986) The composition of body tissues. Br J Radiol; 59: 1209-18. (Pubitemid 17223252)
75. Yu LX, Amidon GL. (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm; 186: 119-25. (Pubitemid 29459038)
76. Zorin S, Kuylenstierna F, Thulin H. (1999) In vitro test of nicotine's permeability through human skin. Risk evaluation and safety aspects. Ann Occup Hyg; 1999: 405-13. (Pubitemid 29414870)